2A Pharma ApS
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP platform. To develop novel, cost effective prophylactic and therapeutic vaccines based on the AAVLP platform for the benefit of both future vaccine recipients and our investors.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
Our Story
The story of the technology started in 2005 when John Nieland, then Head of Immunology at Medigene AG, and colleagues Markus Hörer and Hildegard Büning, discovered how to replace peptides on the surface of a modified adenovirus with antigens to induce and enhance a specific antibody response. The AAVLP inventions were patented in the following years, but the potential was never commercialised as Medigene decided to focus on other projects and John Nieland left the company to pursue new opportunities. In 2014 John Nieland joined Professor Søren Nielsen at Aalborg University and the idea to develop a company around AAVLP was again ignited. John Nieland and Søren Nielsen approached Medigene with their idea and started the discussions about an in-licensing agreement while also exploring funding options. During this process, the team was expanded to include Preben Bruun-Nyzell. 2A Pharma AB was founded on 12 December 2016 in Malmö, Sweden. Shortly thereafter, the company’s first employee, Jeanette Prangsgaard, joined as Project Manager for our lead project and two years after, Mathilde Sanden, joined as Project Manager for the projects in the Research and Development stage.